10x Genomics (TXG) Non-Current Debt (2018 - 2019)
10x Genomics' (TXG) quarterly Non-Current Debt came in at $19.8 million in Q4 2019, down 22.17% year-over-year from $25.5 million in Q4 2018, and down 11.07% quarter-over-quarter from $22.3 million in Q3 2019.
Powered by 
Analysis
10x Genomics (TXG) Non-Current Debt (2018 - 2019) Analysis & Trends
10x Genomics has disclosed Non-Current Debt across 2 years of filings, most recently posting $19.8 million for Q4 2019.
- In Q4 2019, Non-Current Debt fell 22.17% year-over-year to $19.8 million; the TTM figure through Dec 2019 stood at $19.8 million (down 22.17% YoY), while the FY2019 annual figure was $19.8 million, down 22.17% from the prior year.
- Non-Current Debt came in at $19.8 million for Q4 2019 at 10x Genomics, down from $22.3 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $25.5 million in Q4 2018 to a low of $19.8 million in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 226.93 Bn | 222.99 Bn | 8.34 Bn | 42.28 Bn |
| 2 | Danaher | 145.94 Bn | 141.60 Bn | 3.61 Bn | 26.56 Bn |
| 3 | Agilent Technologies | 42.55 Bn | 40.79 Bn | 1.04 Bn | 3.65 Bn |
| 4 | Illumina | 32.95 Bn | 31.78 Bn | 770.00 Mn | 1.49 Bn |
| 5 | Revvity | 14.53 Bn | 13.51 Bn | 416.87 Mn | 2.63 Bn |
| 6 | Bio-Techne | 11.31 Bn | 11.04 Bn | 211.39 Mn | 200.00 Mn |
| 7 | Bio-Rad Laboratories | 10.34 Bn | 8.72 Bn | 345.80 Mn | 1.20 Bn |
| 8 | Repligen | 9.46 Bn | 8.44 Bn | 110.04 Mn | 551.05 Mn |
| 9 | Bruker | 8.91 Bn | 8.73 Bn | 416.00 Mn | 1.81 Bn |
| 10 | 10x Genomics | 8.16 Bn | 7.61 Bn | 112.50 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | 19.84 Mn |
| Sep 30, 2019 | 22.31 Mn |
| Dec 31, 2018 | 25.49 Mn |